Abstract
Between May 1984 and January 1996, 130 patients were replaced cardiac valve using 150 St. Jude Medical prosthetic valves(42 aortic, 68 mitral, 20 aortic and mitral valve replycements). Follow-up was 97.6% complete. The early mortality rate was 5.4%, and late mortality rate was 4.9%. The valve-related late mortality rate was 3.3%. Of late complications, there were 6 anticoagulant related hemorrhages, 4 thromboembolisms and 1 paravalvular leakage. Linearized rates of late complication and valve-related late mortality were as follows: total late complications, .1.68o per patient-year: anticoagulant related hemorrhages, 0.92% per patient-year: thromboembolism, 0.61% per patient-year: paravalvular leakage, 0.15% per patient-year: reoperation, 0.15% per patient-year: and valve-related late mortalities, 0.61% per patient-year. Actuar al event free rate at 10 years was 87.4 $\pm$ 3.2%. The overall actuarial survival rate was 90.4$\pm$2.7% at 5 years, 87.5$\pm$3.3% at 10 years. Ninety eight percent of the survivors were in the New York Heart Association functional class I or II at the end of follow-up. There was significant improvement of cardiothoracic ratio. In conclusion, this study suggests the excellent durability of the St. Jude Medical Heart valve and remarkable functional benefit for the majority of the patients. However, prosthesisrelated complications are still common. Outcome is strongly related to the patient's preoperative cardiac condition and to the adequacy of anticoagulation control.
1984년 5월부터 1996년 1월까지 전북대학교병원 흉부외과에서 130명의 환자에게 51. Jude MEdical기계판막을 이용하여 판막 치환수술을 시행하였다. 승모판 치환술, 대동맥판 치환술, 동시에 승모판 치환술 및 대동맥 판 중복치 환술을 받은 환자는 각각 68례, 42례, 20례이었다. 조기사망은 7례로 전체 환자의 5.4%에서 발생하 였고 조기합병증은 17례(13.1%)에서 발생하였다. 1996년 12월까지 97.6%에서 추적 관찰하였고 추적기간은 최소 5.5개월에서 최대 153.5개월로 평균 63.6$\pm$27.6개월(5.3$\pm$2.3년)이었고 총 추적기간은 678.7환자-년이었다. 판막관련 만기사망은 6례(4.9%)의 만기사망 중 4례(3.3%)이었다. 판막관련 만기 합병증은 11례(9.1%)에서 발 생하였는데 혈전색증(6계), 출혈(4례), 판막주위누출(Irll)이 발생하였다. 판막관련 합병증 발생률(Linearized rate)은 1.68%/환자-년, 항응고제와 관련된 출혈은 0.92%/환자-년, 혈전색증은 0.61%/환자-년, 판막주위 누출은 0.15%/환자-년의 발생빈도를 보였고 재수술률은 0.15%/환자-년(재수술은 1례), 판막관련 만기사망은 0.61%/환자-년의 발생빈도를 보였다. 10년간 합병증이 발생하지 않을 확률은 87.4 \ulcorner.2%이었다. 술후 심흉곽비와 뉴욕 심장학회(NYHA) 기능분류는 수술전후에 뚜렷하게 개선되었다. 수술후 생존율은 5년, 10년에 각각 90.4$\pm$ 2.7%, 87.5$\pm$3.3%이었다.
